BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 21969819)

  • 1. NRF2 mutation confers malignant potential and resistance to chemoradiation therapy in advanced esophageal squamous cancer.
    Shibata T; Kokubu A; Saito S; Narisawa-Saito M; Sasaki H; Aoyagi K; Yoshimatsu Y; Tachimori Y; Kushima R; Kiyono T; Yamamoto M
    Neoplasia; 2011 Sep; 13(9):864-73. PubMed ID: 21969819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nrf2 is useful for predicting the effect of chemoradiation therapy on esophageal squamous cell carcinoma.
    Kawasaki Y; Okumura H; Uchikado Y; Kita Y; Sasaki K; Owaki T; Ishigami S; Natsugoe S
    Ann Surg Oncol; 2014 Jul; 21(7):2347-52. PubMed ID: 24599410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of decreased expression of long non-coding RNA LOC285194 with chemoradiotherapy resistance and poor prognosis in esophageal squamous cell carcinoma.
    Tong YS; Zhou XL; Wang XW; Wu QQ; Yang TX; Lv J; Yang JS; Zhu B; Cao XF
    J Transl Med; 2014 Aug; 12():233. PubMed ID: 25169763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of miRNA-based molecular diagnostics and treatment of NRF2-stabilized tumors.
    Yamamoto S; Inoue J; Kawano T; Kozaki K; Omura K; Inazawa J
    Mol Cancer Res; 2014 Jan; 12(1):58-68. PubMed ID: 24307696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer.
    Shibata T; Kokubu A; Gotoh M; Ojima H; Ohta T; Yamamoto M; Hirohashi S
    Gastroenterology; 2008 Oct; 135(4):1358-1368, 1368.e1-4. PubMed ID: 18692501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The telomere/telomerase binding factor PinX1 is a new target to improve the radiotherapy effect of oesophageal squamous cell carcinomas.
    Qian D; Zhang B; He LR; Cai MY; Mai SJ; Liao YJ; Liu YH; Lin MC; Bian XW; Zeng YX; Huang JJ; Kung HF; Xie D
    J Pathol; 2013 Apr; 229(5):765-74. PubMed ID: 23341363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nrf2 and Keap1 abnormalities in esophageal squamous cell carcinoma and association with the effect of chemoradiotherapy.
    Zhang J; Jiao Q; Kong L; Yu J; Fang A; Li M; Yu J
    Thorac Cancer; 2018 Jun; 9(6):726-735. PubMed ID: 29675925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of AIB1 predicts resistance to chemoradiotherapy and poor prognosis in patients with primary esophageal squamous cell carcinoma.
    He LR; Liu MZ; Li BK; Rao HL; Deng HX; Guan XY; Zeng YX; Xie D
    Cancer Sci; 2009 Sep; 100(9):1591-6. PubMed ID: 19552757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical significance of the gene expression profile in residual tumor cells after neoadjuvant chemo-radiotherapy for esophageal cancer.
    Tanaka K; Otake K; Mohri Y; Ohi M; Yokoe T; Toiyama Y; Miki C; Tonouchi H; Kusunoki M
    Oncol Rep; 2009 Jun; 21(6):1489-94. PubMed ID: 19424628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p53 Mutation status predicts pathological response to chemoradiotherapy in locally advanced esophageal cancer.
    Makino T; Yamasaki M; Miyata H; Yoshioka S; Takiguchi S; Fujiwara Y; Nakajima K; Nishida T; Mori M; Doki Y
    Ann Surg Oncol; 2010 Mar; 17(3):804-11. PubMed ID: 19885698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MiR-27b-3p exerts tumor suppressor effects in esophageal squamous cell carcinoma by targeting Nrf2.
    Han M; Li N; Li F; Wang H; Ma L
    Hum Cell; 2020 Jul; 33(3):641-651. PubMed ID: 32419118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utility of weekly docetaxel combined with preoperative radiotherapy for locally advanced esophageal cancer from pathological analysis.
    Kushida T; Nohara S; Yoshino K; Fujiwara D; Ouchi K; Amano T; Isayama F; Tomita N; Iwanuma Y; Sasai K; Tsurumaru M; Kajiyama Y
    Dis Esophagus; 2014; 27(4):368-73. PubMed ID: 23865505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dysregulation of SOX17/NRF2 axis confers chemoradiotherapy resistance and emerges as a novel therapeutic target in esophageal squamous cell carcinoma.
    Hsieh CH; Kuan WH; Chang WL; Kuo IY; Liu H; Shieh DB; Liu H; Tan B; Wang YC
    J Biomed Sci; 2022 Oct; 29(1):90. PubMed ID: 36310172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRCA1 mRNA expression as a predictive and prognostic marker in advanced esophageal squamous cell carcinoma treated with cisplatin- or docetaxel-based chemotherapy/chemoradiotherapy.
    Gao Y; Zhu J; Zhang X; Wu Q; Jiang S; Liu Y; Hu Z; Liu B; Chen X
    PLoS One; 2013; 8(1):e52589. PubMed ID: 23326344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating mRNA Profiling in Esophageal Squamous Cell Carcinoma Identifies FAM84B As A Biomarker In Predicting Pathological Response to Neoadjuvant Chemoradiation.
    Hsu FM; Cheng JC; Chang YL; Lee JM; Koong AC; Chuang EY
    Sci Rep; 2015 May; 5():10291. PubMed ID: 25980316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. COX2 expression predicts resistance to chemoradiotherapy in esophageal squamous cell carcinoma.
    Akutsu Y; Hanari N; Yusup G; Komatsu-Akimoto A; Ikeda N; Mori M; Yoneyama Y; Endo S; Miyazawa Y; Matsubara H
    Ann Surg Oncol; 2011 Oct; 18(10):2946-51. PubMed ID: 21437756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene-expression signature regulated by the KEAP1-NRF2-CUL3 axis is associated with a poor prognosis in head and neck squamous cell cancer.
    Namani A; Matiur Rahaman M; Chen M; Tang X
    BMC Cancer; 2018 Jan; 18(1):46. PubMed ID: 29306329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct Downregulation of B-Cell Translocation Gene 3 by microRNA-93 Is Required for Desensitizing Esophageal Cancer to Radiotherapy.
    Cui H; Zhang S; Zhou H; Guo L
    Dig Dis Sci; 2017 Aug; 62(8):1995-2003. PubMed ID: 28434073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. REG1A expression status suggests chemosensitivity among advanced thoracic esophageal squamous cell carcinoma patients treated with esophagectomy followed by adjuvant chemotherapy.
    Sato Y; Motoyama S; Nanjo H; Ito S; Yoshino K; Sasaki T; Kuribayashi K; Nagaki Y; Imai K; Saito H; Minamiya Y; Ogawa J
    Ann Surg Oncol; 2013 Sep; 20(9):3044-51. PubMed ID: 23645481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNA-330-5p as a Putative Modulator of Neoadjuvant Chemoradiotherapy Sensitivity in Oesophageal Adenocarcinoma.
    Bibby BA; Reynolds JV; Maher SG
    PLoS One; 2015; 10(7):e0134180. PubMed ID: 26221725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.